Zhejiang Taimei Medical Technology Co., Ltd.
Zhejiang Taimei Medical Technology Co., Ltd. provides digital operation platform for the biopharma industry in China. The company offers TrialOS, a drug digital cooperation platform that connects the cycle of hospitals, pharmaceutical companies, third-party providers, regulatory authorities, patients, and other industry stakeholders; PharmaOS, a pharmaceutical digital marketing platform; and Ente… Read more
Zhejiang Taimei Medical Technology Co., Ltd. (A2V) - Net Assets
Latest net assets as of June 2025: €1.22 Billion EUR
Based on the latest financial reports, Zhejiang Taimei Medical Technology Co., Ltd. (A2V) has net assets worth €1.22 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.52 Billion) and total liabilities (€302.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.22 Billion |
| % of Total Assets | 80.11% |
| Annual Growth Rate | -4.35% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 17.62 |
Zhejiang Taimei Medical Technology Co., Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how Zhejiang Taimei Medical Technology Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang Taimei Medical Technology Co., Ltd. (2021–2024)
The table below shows the annual net assets of Zhejiang Taimei Medical Technology Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.23 Billion | +18.47% |
| 2023-12-31 | €1.04 Billion | -24.67% |
| 2022-12-31 | €1.38 Billion | -1.96% |
| 2021-12-31 | €1.41 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Taimei Medical Technology Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 97429400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.86 Billion | 247.09% |
| Total Equity | €1.16 Billion | 100.00% |
Zhejiang Taimei Medical Technology Co., Ltd. Competitors by Market Cap
The table below lists competitors of Zhejiang Taimei Medical Technology Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CrystalGenomics Inc
KQ:083790
|
$48.18 Million |
|
Plastron Precision Co Ltd
TWO:6185
|
$48.19 Million |
|
Marmaris Altinyunus Turistik Tesisleri AS
IS:MAALT
|
$48.19 Million |
|
Leo Lithium Limited
PINK:LLLAF
|
$48.19 Million |
|
Ramayana Lestari Sentosa Tbk
JK:RALS
|
$48.16 Million |
|
Prairie Operating Co.
F:7C5
|
$48.16 Million |
|
EURO PRATIK SALES LIMITED
NSE:EUROPRATIK
|
$48.13 Million |
|
Thai Nguyen International Hospital JSC
VN:TNH
|
$48.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Taimei Medical Technology Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 978,327,000 to 1,157,810,000, a change of 179,483,000 (18.3%).
- Net loss of 214,609,000 reduced equity.
- New share issuances of 291,057,000 increased equity.
- Other factors increased equity by 103,035,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-214.61 Million | -18.54% |
| Share Issuances | €291.06 Million | +25.14% |
| Other Changes | €103.03 Million | +8.9% |
| Total Change | €- | 18.35% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Taimei Medical Technology Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.25x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.52 | €0.52 | x |
| 2022-12-31 | €2.34 | €0.52 | x |
| 2023-12-31 | €1.75 | €0.52 | x |
| 2024-12-31 | €2.05 | €0.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Taimei Medical Technology Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -38.94%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.37x
- Recent ROE (-18.54%) is above the historical average (-29.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -33.99% | -102.88% | 0.26x | 1.28x | €-620.71 Million |
| 2022 | -31.52% | -75.18% | 0.30x | 1.39x | €-543.90 Million |
| 2023 | -35.45% | -60.51% | 0.40x | 1.48x | €-444.61 Million |
| 2024 | -18.54% | -38.94% | 0.35x | 1.37x | €-330.39 Million |
Industry Comparison
This section compares Zhejiang Taimei Medical Technology Co., Ltd.'s net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $1,892,348,407
- Average return on equity (ROE) among peers: -9.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Taimei Medical Technology Co., Ltd. (A2V) | €1.22 Billion | -33.99% | 0.25x | $48.17 Million |
| Schrödinger, Inc. (43Z) | $557.09 Million | -18.02% | 0.36x | $643.71 Million |
| DACHA STRATEGIC (7DC) | $40.24 Million | 0.65% | 0.08x | $81.97 Million |
| ABL Diagnostics Société anonyme (9BK0) | $6.77 Million | 0.80% | 1.20x | $391.61K |
| ASCOM HLDG NA SF 0,50 (AH2N) | $80.00 Million | 16.88% | 1.43x | $190.62 Million |
| DocCheck AG (AJ91) | $18.14 Million | 3.32% | 0.15x | $17.70 Million |
| EM Systems Co. Ltd (EMO) | $17.69 Billion | 7.87% | 0.33x | $74.55 Million |
| Tempus AI (F3M) | $-1.38 Billion | 0.00% | 0.00x | $4.75 Billion |
| Pangenomic Health Inc. (LL3) | $2.24 Million | -118.14% | 0.15x | $4.82 Million |
| MeVis Medical Solutions AG (M3V) | $17.83 Million | 17.76% | 0.45x | $12.99 Million |